4//SEC Filing
Lazar David E. 4
Accession 0000921895-25-002764
CIK 0001389545other
Filed
Oct 16, 8:00 PM ET
Accepted
Oct 17, 5:28 PM ET
Size
6.6 KB
Accession
0000921895-25-002764
Insider Transaction Report
Form 4
Lazar David E.
10% Owner
Transactions
- Sale
Series D Convertible Preferred Stock
2025-10-16−441,325→ 39,925 total→ Common Stock (70,612,000 underlying)
Footnotes (3)
- [F1]The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. Each share of Series D Preferred Stock is convertible into 160 shares of the Common Stock of NovaBay Pharmaceuticals, Inc. (the "Issuer") at any time, subject to certain ownership limitations.
- [F2]The Series D Preferred Stock is exercisable immediately upon issuance, is perpetual and has no expiration date.
- [F3]On October 9, 2025, David E. Lazar (the "Reporting Person") entered into a Securities Purchase Agreement with R01 Fund LP ("R01 LP") and Framework Ventures IV L.P. ("Framework" and together with R01 LP, the "Purchasers") pursuant to which the Purchasers agreed to acquire from the Reporting Person all of the Reporting Person's right, title and interest in (i) an aggregate of 441,325 shares of Series D Preferred Stock for $9,850,000 and (ii) the rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000 payable to the Issuer. The closing of the transaction occurred on October 16, 2025 following the Issuer's annual meeting of stockholders.
Documents
Issuer
NovaBay Pharmaceuticals, Inc.
CIK 0001389545
Entity typeother
Related Parties
1- filerCIK 0001932843
Filing Metadata
- Form type
- 4
- Filed
- Oct 16, 8:00 PM ET
- Accepted
- Oct 17, 5:28 PM ET
- Size
- 6.6 KB